+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncology Based In-Vivo CRO Market - Global Forecast 2026-2032- Product Image
Oncology Based In-Vivo CRO Market - Global Forecast 2026-2032- Product Image
New

Oncology Based In-Vivo CRO Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 184 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888779
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The oncology-based in-vivo CRO market is evolving rapidly as pharmaceutical stakeholders seek more advanced preclinical insights, rigorous study designs, and operational agility to support the next generation of cancer therapies. Senior decision-makers must navigate increasing complexity in model selection, regulatory expectations, and technology adoption to realize translational outcomes.

Market Snapshot: Oncology-Based In-Vivo CRO Market

The Oncology-Based In-Vivo CRO Market expanded from USD 1.57 billion in 2025 to USD 1.76 billion in 2026 and is projected to grow at a CAGR of 11.76%, reaching USD 3.43 billion by 2032. This growth is driven by heightened demand for integrated preclinical services, robust operational models, and comprehensive data to advance cancer research and clinical translation efficiently across regions.

Scope & Segmentation of the Preclinical Oncology In-Vivo Ecosystem

  • Model Types: Genetically engineered mouse models, immunocompetent syngeneic systems, mouse xenografts, and non-murine species such as dog, rabbit, and rat each provide unique advantages for meeting diverse translational and regulatory objectives.
  • Therapeutic Modalities: Study protocols are tailored to address the distinct requirements of chemotherapy, immunotherapy, and targeted therapies, incorporating biomarker analysis, PK/PD profiling, and immunogenicity assessment.
  • Routes of Administration: Options range from intravenous and oral to subcutaneous delivery, selected according to study needs for pharmacokinetics, formulation, and dosing patterns.
  • End Users: Academic laboratories, pharmaceutical sponsors, and dedicated contract research organizations leverage in-vivo studies for scientific rigor, accelerated timelines, and compliance with quality standards.
  • Regional Coverage: The market spans the Americas, Europe, Middle East & Africa, and Asia-Pacific, each region presenting specific infrastructure capabilities, regulatory environments, and logistical demands.
  • Enabling Technologies: Innovations such as advanced immune monitoring, sophisticated PK/PD analytics, and novel model engineering improve data reliability and increase the efficiency of clinical translation.

Key Takeaways for Senior Decision-Makers

  • Matching in-vivo model selection and administration routes to study goals enhances biological relevance and helps manage translational risk throughout project lifecycles.
  • Progress in genetic engineering and engraftment technologies elevates expectations for reproducibility, placing new demands on specialized CRO expertise.
  • Growth in immunotherapy and targeted therapy pipelines requires access to integrated biomarker platforms and robust analytical support.
  • Maintaining operational resilience now depends on secure supply chains, stringent biosafety, and highly skilled project teams for seamless delivery of complex preclinical studies.
  • Providers with advanced quality control, reproducible methodologies, and strong advisory capabilities deliver greater alignment with evolving clinical development strategies.
  • Regional choices for preclinical study placement hinge on the interplay of infrastructure, regulatory processes, and consistent access to high-quality translational data.

Tariff Impact: Navigating Volatility and Supply Chain Strategy

Recent tariff policies have added uncertainty to procurement and study planning for oncology-based in-vivo CROs. Organizations mitigate volatility by broadening supplier bases, aggregating procurement, and seeking local sourcing to reduce exposure to abrupt price fluctuations. Clear contract frameworks addressing change orders, force majeure, and passing on costs protect against unforeseen disruptions and support continuity in study execution. Flexible approach to vendor management and proactive scenario planning further strengthens resilience across the supply chain, sustaining momentum for preclinical projects.

Methodology & Data Sources

This report draws from expert interviews, technical evaluations of in-vivo oncology model performance, and operational benchmarking of global service providers in the CRO landscape. Segmentation was verified through systematic review of model characteristics, regional regulatory conditions, and logistical factors to minimize bias and support clear, actionable insights for stakeholders.

Why This Report Matters

  • Enables informed preclinical investment by revealing where operational challenges and translational opportunities are most concentrated.
  • Facilitates smarter study placement through comprehensive segmentation and a detailed understanding of region-specific market dynamics.
  • Provides actionable guidance to align supply chain policy, contract management, and scientific design with broader clinical development goals.

Conclusion

[ImageId=6ccf270c-f569-4cb0-9655e71080d0] Excellence in oncology-based in-vivo CROs rests on integrating scientific rigor, operational resilience, and strategic foresight. These elements are essential for advancing preclinical studies into successful clinical programs amid a rapidly evolving global market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Oncology Based In-Vivo CRO Market, by Animal Model
8.1. Murine
8.1.1. Genetically Engineered Mouse Model
8.1.2. Immunocompetent Syngeneic
8.1.3. Mouse Xenograft
8.2. Non Murine
8.2.1. Dog
8.2.2. Rabbit
8.2.3. Rat
9. Oncology Based In-Vivo CRO Market, by Route Of Administration
9.1. Intravenous
9.2. Oral
9.3. Subcutaneous
10. Oncology Based In-Vivo CRO Market, by Therapeutic Modality
10.1. Chemotherapy
10.2. Immunotherapy
10.2.1. Checkpoint Inhibitors
10.2.2. Monoclonal Antibodies
10.3. Targeted Therapy
10.3.1. Kinase Inhibitors
10.3.2. Small Molecule Inhibitors
11. Oncology Based In-Vivo CRO Market, by End User
11.1. Academia & Research Institute
11.2. Contract Research Organization
11.3. Pharmaceutical
12. Oncology Based In-Vivo CRO Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Oncology Based In-Vivo CRO Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Oncology Based In-Vivo CRO Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Oncology Based In-Vivo CRO Market
16. China Oncology Based In-Vivo CRO Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Bioanalytical Systems, Inc.
17.6. Celerion, Inc.
17.7. Champion Oncology, Inc.
17.8. Charles River Laboratories International, Inc.
17.9. Crown Bioscience, Inc.
17.10. Explora BioLabs, Inc.
17.11. Frontage Laboratories, Inc.
17.12. GenScript Biotech Corporation
17.13. GenScript ProBio Co., Ltd.
17.14. Inotiv, Inc.
17.15. JSR Life Sciences Corporation
17.16. KCR S.A.
17.17. Laboratory Corporation of America Holdings
17.18. Living Tumor Laboratory, Inc.
17.19. MPI Research, Inc.
17.20. Oncodesign SA
17.21. Parexel International Corporation
17.22. PRA Health Sciences, Inc.
17.23. Syneos Health, Inc.
17.24. Taconic Biosciences, Inc.
17.25. The Jackson Laboratory, Inc.
17.26. Toxikon Corporation
17.27. Translational Drug Development, Inc.
17.28. WuXi AppTec Co., Ltd.
List of Figures
FIGURE 1. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 112. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 113. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 114. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 115. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 116. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 117. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 118. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 130. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 131. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 132. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 133. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 134. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 135. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 136. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 149. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 150. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 151. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 153. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 154. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 155. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 158. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 159. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 160. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 161. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 162. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 163. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 164. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 176. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 177. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 178. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 179. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 180. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 181. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 182. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 185. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 186. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 187. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 189. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 190. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 191. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 194. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 195. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 196. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 197. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 198. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 199. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 200. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 208. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 210. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
TABLE 213. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
TABLE 214. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
TABLE 215. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 216. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 217. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 218. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 219. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Oncology Based In-Vivo CRO market report include:
  • Bioanalytical Systems, Inc.
  • Celerion, Inc.
  • Champion Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • Explora BioLabs, Inc.
  • Frontage Laboratories, Inc.
  • GenScript Biotech Corporation
  • GenScript ProBio Co., Ltd.
  • Inotiv, Inc.
  • JSR Life Sciences Corporation
  • KCR S.A.
  • Laboratory Corporation of America Holdings
  • Living Tumor Laboratory, Inc.
  • MPI Research, Inc.
  • Oncodesign SA
  • Parexel International Corporation
  • PRA Health Sciences, Inc.
  • Syneos Health, Inc.
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory, Inc.
  • Toxikon Corporation
  • Translational Drug Development, Inc.
  • WuXi AppTec Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages184
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.76 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.43 Billion
Compound Annual Growth Rate11.7%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

In Vivo CRO Market - Global Forecast 2026-2032 - Product Image

In Vivo CRO Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Oncology Based In-Vivo CRO Market Report and Forecast 2025-2034 - Product Image

Oncology Based In-Vivo CRO Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Oncology Based In-Vivo CRO - Global Strategic Business Report - Product Image

Oncology Based In-Vivo CRO - Global Strategic Business Report

  • Report
  • 129 Pages
  • Global
From
Oncology Based in-Vivo CRO Market Report 2025 - Product Image

Oncology Based in-Vivo CRO Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Oncology Based in-Vivo CRO Market Report by Indication, Model, Application, and Region 2025-2033 - Product Image

Oncology Based in-Vivo CRO Market Report by Indication, Model, Application, and Region 2025-2033

  • Report
  • 148 Pages
  • Global
From

About the Oncology Based In Vivo CRO Market

The Oncology Based In Vivo CRO market is a subset of the biotechnology industry that focuses on providing preclinical services for oncology drug development. These services include animal models, pharmacology, toxicology, and imaging studies. The goal of these services is to provide data that can be used to support the safety and efficacy of oncology drugs. The market is driven by the increasing demand for new treatments for cancer, as well as the need for more efficient and cost-effective drug development. The Oncology Based In Vivo CRO market is highly competitive, with a number of companies offering services in this area. Some of the major players in the market include Charles River Laboratories, Covance, WIL Research, and Envigo. Other companies in the market include MPI Research, SRI International, and Taconic Biosciences. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.